Amgen Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Amgen Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Thousand Oaks
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- AMGN
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0000318154
- EIN
- 95-3540776
Board of directors
-
Amy E. Miles · DirectorSince 2023
-
Brian Druker · DirectorSince 2023
-
Charles M. Holley · DirectorSince 2023
-
Ellen Jamison Kullman · DirectorSince 2023
-
Greg C. Garland · DirectorSince 2023
-
Mary E. Klotman · DirectorSince 2024
-
Michael Drake V · DirectorSince 2023
-
Omar Ishrak · DirectorSince 2023
-
R. Sanders Williams · DirectorSince 2023
-
Robert A. Bradway · Director · Chairman, CEO and PresidentSince 2023
-
Robert Eckert · DirectorSince 2023
-
Ronald D. Sugar · DirectorSince 2023
-
Tyler Jacks · DirectorSince 2023
-
Wanda M. Austin · DirectorSince 2023
Chief executives
Robert A. Bradway
· Chairman, CEO and President
Dates unknown
Director election results
Annual meeting of May 19, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
94.8%
-
95.0%
-
95.3%
-
97.1%
-
97.7%
-
98.4%
-
98.7%
-
98.8%
-
98.9%
-
99.0%
-
99.3%
Board connections
11 of this board's directors also sit on 17 other boards.
- via Ronald D. Sugar and Wanda M. Austin
- via Amy E. Miles and Charles M. Holley
- via Charles M. Holley and Greg C. Garland
- via Robert Eckert and Ronald D. Sugar
- via Wanda M. Austin
- via Ellen Jamison Kullman
- via Omar Ishrak
- via R. Sanders Williams
- via Robert Eckert
- via Robert Eckert
- via Amy E. Miles
- via R. Sanders Williams
- via Robert A. Bradway
- via Amy E. Miles
- via Ellen Jamison Kullman
- via Tyler Jacks
- via Wanda M. Austin
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $29,330,765
- 14 sales by 6 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 13, 2026 | Khosla Rachna Officer (SVP, Business Development) | Option exercise | +1,252 | $162.60 | $203,575 |
| Aug 13, 2026 | Khosla Rachna Officer (SVP, Business Development) | Open-market sale | −1,252 | $416.43 | $521,365 |
| Aug 11, 2026 | Khosla Rachna Officer (SVP, Business Development) | Open-market sale | −2,000 | $412.57 | $825,134 |
| Aug 7, 2026 | Michael Drake V Director | Grant or award | +64 | — | — |
| Aug 7, 2026 | Charles M. Holley Director | Grant or award | +103 | — | — |
| Aug 7, 2026 | Omar Ishrak Director | Grant or award | +85 | — | — |
| Aug 7, 2026 | Busch Matthew C. Officer (VP, Finance & CAO) | Grant or award | +730 | — | — |
| Aug 6, 2026 | Grygiel Nancy A. Officer (SVP & CCO) | Option exercise | +1,970 | $177.46 | $349,596 |
| Aug 6, 2026 | Miller Derek Officer (SVP, Human Resources) | Option exercise | +2,069 | $162.60 | $336,419 |
| Aug 6, 2026 | Grygiel Nancy A. Officer (SVP & CCO) | Open-market sale | −1,970 | $402.16 | $792,255 |
| Aug 6, 2026 | Miller Derek Officer (SVP, Human Resources) | Open-market sale | −2,069 | $402.54 | $832,864 |
| Aug 6, 2026 | Grygiel Nancy A. Officer (SVP & CCO) | Option exercise | +1,000 | $177.31 | $177,310 |
| Aug 6, 2026 | Miller Derek Officer (SVP, Human Resources) | Option exercise | +1,821 | $177.46 | $323,155 |
| Aug 6, 2026 | Grygiel Nancy A. Officer (SVP & CCO) | Open-market sale | −1,000 | $402.16 | $402,160 |
| Aug 6, 2026 | Miller Derek Officer (SVP, Human Resources) | Open-market sale | −1,821 | $402.54 | $733,033 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.